From the advertisement:
Cytotoxic Therapies Market to 2017
Cytotoxic Therapies Market is Set to
Experience Marginal Decline in the Forecast Period
The cytotoxic therapies market accounted
for $6.5 billion in revenue in 2002 from its eight major indications, which
include breast cancer, cervical cancer, colorectal cancer, head and neck
cancer, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer and
prostate cancer. From 2002, the market grew at a compound annual growth rate
(CAGR) of 5.8%, to $10.1 billion in 2010, and it is estimated to decline
marginally at (0.1%) during the forecast period to produce revenues of $10.1
billion in 2017.
The average annual cost of therapy for
cytotoxic therapies is estimated to decrease moderately over the forecast
period, and is expected to reach an approximate value of $7,667 by 2017.
Overall, the cytotoxic therapies market value will decrease moderately between
2010 and 2017.
Increasing Acceptance of Combinations of
Cytotoxic Medicines with Monoclonal Antibodies will counter the Use of Generics
The therapeutic capabilities of biologics
in controlling and treating oncology complications have led to their widespread
use and popularity amongst patients and prescribers alike. This has convinced
pharmaceutical manufacturers to commence label extensions of their present
portfolio of biologics for multiple oncology complications, even in combination
with cytotoxic medicines. This will act as a support to the continued use of
cytotoxic drugs, even though safety issues exist.
In addition, industry trends suggest that
pharmaceutical companies are more interested in researching and developing
novel targeted therapies and biologics rather than discovering novel cytotoxic
drugs, as these continue to have major safety hurdles. Safety is an important
measure, not only during approval but also when determining reimbursement
lists. Reimbursements for almost all therapeutic areas are under severe
pressure. Taken together, the industry and environmental trends suggest that
the cytotoxic medicines market is likely to see a slow increase in market value
within the next few years.
Well, let’s
check this forecast in 2017. Biologics and targeted treatments promise a lot
and they are very often being screwed up. My forecast that until 2020 we will
witness very nice Black Swan in cytotoxics. Future will show who is right…
No comments:
Post a Comment